Pluri Inc. (PLUR)
NASDAQ: PLUR · Real-Time Price · USD
2.120
+0.025 (1.19%)
At close: Jun 24, 2026, 4:00 PM EDT
2.190
+0.070 (3.30%)
Pre-market: Jun 25, 2026, 6:12 AM EDT
Pluri Employees
As of June 30, 2025, Pluri had 142 total employees, including 127 full-time and 15 part-time employees. The number of employees increased by 24 or 20.34% compared to the previous year.
Employees
142
Change (1Y)
24
Growth (1Y)
20.34%
Revenue / Employee
$7,599
Profits / Employee
-$179,852
Market Cap
22.87M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Jun 30, 2025 | 142 | 24 | 20.34% | 127 | 15 |
| Jun 30, 2024 | 118 | -16 | -11.94% | 106 | 12 |
| Jun 30, 2023 | 134 | -25 | -15.72% | 123 | 11 |
| Jun 30, 2022 | 159 | -3 | -1.85% | 154 | 5 |
| Jun 30, 2021 | 162 | 4 | 2.53% | 153 | 9 |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Celularity | 115 |
| Longeveron | 38 |
| Palatin Technologies | 29 |
| Quantum BioPharma | 17 |
| Cellectar Biosciences | 11 |
| VYNE Therapeutics | 10 |
| Allarity Therapeutics | 8 |
| Neuphoria Therapeutics | 8 |
PLUR News
- 8 days ago - Plurilock Announces Results of Annual General Meeting - Newsfile Corp
- 22 days ago - Pluri Advances Toward U.S. Commercial Launch Through Its Subsidiary Cellav, Following Completion of Regenerative Aesthetic Products Listing - GlobeNewsWire
- 3 months ago - Pluri announces additional $2.5M investment from Alejandro Weinstein - TheFly
- 4 months ago - Pluri secures global IP position with CNIPA for immune cell expansion - TheFly
- 5 months ago - Pluri completes first phase of program with Resbiomed Technologies OOD - TheFly
- 6 months ago - Pluri announces expansion of manufacturing agreement with Remedy Cell - TheFly
- 6 months ago - Pluri and Remedy Cell Expand Collaboration; Successful Engineering Runs and Clinical-Grade Manufacturing Achieved - GlobeNewsWire
- 7 months ago - Pluri appoints Weinstein as Chairman of the Board of Directors - TheFly